PTC Therapeutics (PTCT) Tops Q3 EPS by $1.32

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of $0.20, $1.32 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $211 million versus the consensus estimate of $174.39 million.

GUIDANCE:

PTC Therapeutics sees FY2025 revenue of $750-800 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance